File: '\\swfile\EmailIn\20240227 130158 Attachment 2024_02_27 ENBI NR effective date of share consolidation.docx'

Entheon Biomedical Announces Effective Date of Share Consolidation

VANCOUVER, BC, February 27, 2024 - Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") announces that, further to its news release dated February 21, 2024, the Company confirms the effective date for the consolidation of one (1) post-consolidation share for every ten (10) pre-consolidation shares.

Effective at the opening on Friday, March 1, 2024, the shares of the Company will commence trading on the Canadian Securities Exchange on a consolidated basis. The name and stock symbol share remain the same.

Post-Consolidation Capitalization: Unlimited common shares with no par value of which approximately 5,908,926 common shares are issued and outstanding.

Transfer Agent: Olympia Trust Company

Trading Symbol: ENBI

CUSIP Number: 29383X202 (new)

Record Date: March 4, 2024

About Entheon Biomedical Corp.

Entheon is a biotechnology research and development company interested in treating addiction and substance use disorders.

On Behalf of the Board of Directors,

Timothy Ko, CEO, President and Director

For more information, please contact the Company at:

Entheon Biomedical Corp.

Timothy Ko, CEO

timothy@entheonbiomedical.com

https://entheonbiomedical.com